Illumina, Inc. develops, manufactures, and markets sequencing- and array-based solutions for genetic and genomic analysis worldwide, including in the Americas, Europe, Greater China, the Asia Pacific,... Illumina, Inc. develops, manufactures, and markets sequencing- and array-based solutions for genetic and genomic analysis worldwide, including in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company provides instruments and consumables such as reagents, flow cells, and library preparation kits, along with whole-genome sequencing kits for genomes of varying size and complexity, and targeted resequencing kits for exomes, specific genes, RNA, and other genomic regions. Its offerings support whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services, serving research, clinical, and applied markets through the Core Illumina segment. These technologies enable large-scale analysis of genetic variation and function, powering advancements in life science research, translational and consumer genomics, and molecular diagnostics. Founded in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers innovative, flexible, and scalable platforms to meet diverse customer needs in genomic solutions.
We have not yet reviewed Illumina's disclosures for Group Entities data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.